FA
MYGN icon

FDx Advisors’s Myriad Genetics MYGN Stock Holding History

FDx Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-14,267
Closed -$555K – 983
2014
Q2 		$555K Buy
14,267
+776
+6% +$28.9K 0.04% 538
2014
Q1 		$461K Buy
+13,491
New +$418K 0.04% 460

Other funds holding MYGN

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

FDx Advisors's MYGN Position: Q3 2014 in Review

FDx Advisors sold out of Myriad Genetics (MYGN) in Q3 2014, closing a stake of 14,267 shares — an estimated $555K sold.

FDx Advisors first reported a position in MYGN in Q1 2014 and held it in 2 quarters. The position peaked at $555K in Q2 2014. 275 funds tracked by Wall St. Rank hold MYGN as of Q3 2014.

  • FDx Advisors reported no remaining Myriad Genetics position as of Q3 2014 after selling out during the quarter.
  • FDx Advisors sold 14,267 Myriad Genetics shares in Q3 2014, an estimated $555K.
  • FDx Advisors first reported a position in Myriad Genetics in Q1 2014 and held it in 2 quarters.
  • FDx Advisors's Myriad Genetics position peaked at $555K in Q2 2014.
  • 275 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2014.

Based on FDx Advisors's 13F filing for Q3 2014, filed 17 Nov 2014.